linjc16/ctgov huggingface dataset:
Assessment of Trunk Aesthetics: Development of a New Tool

Study Overview
=================
Brief Summary
-----------------
Scoliosis is a three-dimensional deformity of the spine and the trunk. TRACE (Trunk Aesthetic Clinical Evaluation) is an aesthetics assessment tool for patients with scoliosis. It has been validated with Rasch analysis is easily usable in daily clinical practice. Despite this tool being more sensitive in detecting changes in aesthetics during treatment compared to other existing ones, its reliability is still low, probably due to the small number of elements that make up the rating scale. This study aims to develop a new version of the TRACE tool by adding new items. The development of TRACE2 in a Rasch environment will ensure greater sensitivity and specificity of the scale assessment.

Official Title
-----------------
TRACE2: Development of a New Tool for the Evaluation of the Trunk Aesthetics in Patients With Scoliosis

Conditions
-----------------
Adolescent Idiopathic Scoliosis

Intervention / Treatment
-----------------
* Other: TRACE 2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of scoliosis age between 10 and 17 years old scoliosis >10° Cobb humps > 5° ATR Exclusion Criteria: History of spinal surgery positive neurological assessment

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Trunk Aesthetic Clinical Evaluation<br> | Other: TRACE 2<br>* The first version of TRACE2 will be retrospectively verified through its application by experts on 150 photos of scoliosis patients who agreed to use the material produced for clinical use for retrospective research. Both intra-operator and inter-operator repeatability will be evaluated and a first Rasch analysis will be performed. The new version of TRACE2 (TRACE2.2) obtained following the retrospective validation on the photos will be verified prospectively through its application by the experts on 150 patients in specialist medical examination. Both intra-operator and inter-operator repeatability will be evaluated and further Rasch analysis will follow. On the basis of the results obtained from the analysis, the new TRACE2 scale (TRACE2.3) will then be applied to a further 150 patients, its intra- and inter-operator repeatability will be calculated and a final Rasch analysis will be performed to arrive at the final version of the scale (TRACE2.4).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TRACE2 | New version of the TRACE tool for the assessment of trunk aesthetics in patients with scoliosis | through study completion, an average of 1 year |
A Correlation Study of Internal Jugular Vein Variability Under Deep Inhalation and Propofol-induced Hypotension

Study Overview
=================
Brief Summary
-----------------
The correlation between internal jugular vein variability during deep inhalation and the decrease in blood pressure during propofol induction.

Detailed Description
-----------------
Ultrasound records at least one quiet breathing cycle and one deep inhalation cycle to calculate IJVV Propofol was infused target-controlled at 4 μg/ml, and changes in arterial blood pressure within 3 minutes of propofol induction were observed. Aim to conduct a prospective observational study to evaluate the correlation between internal jugular vein variability during deep inhalation and the decrease in blood pressure during propofol induction.

Official Title
-----------------
A Correlation Study of Internal Jugular Vein Variability Under Deep Inhalation and Propofol-induced Hypotension

Conditions
-----------------
Hemodynamic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age over 60 years American Society of Anesthesiology (ASA) status Ⅱ-Ⅲ Surgery with radial artery puncture Propofol induction Exclusion Criteria: BMI≥30kg/m2 People with short necks; Previous hypotension (systolic blood pressure <90mmHg or mean arterial pressure <65mmHg) Previous poorly controlled hypertension Cardiac insufficiency , EF value<50% Upper limb deep vein thrombosis History of radiotherapy or neck surgery Inability to maintain a supine position for necessary measurements Mechanical ventilation status or inability to take deep breaths patients gastrointestinal surgery patients allergic to propofol.

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IJVV during deep inhalation | IJVV (%) = (diamax - diamin)/[(diamax + diamin)/2] × 100 | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Internal jugular vein, propofol, hypotension, hemodynamic
Optimizing Treatments for Heart Failure During Hospitalization

Study Overview
=================
Brief Summary
-----------------
Heart failure reaches 1.5 million people in France and is responsible for 200,000 hospitalizations per year. Over the past ten years, new therapies have emerged (treatment of martial deficiency, Entresto, iSGLT2). Hospitalization in a context of acute heart failure is a moment of choice in the history of the disease to introduce recommended treatments under closer supervision (clinical, biological) than in ambulatory, and allows a decrease in hospitalizations, morbidity and mortality. The purpose of this study is to describe the introduction of heart failure drugs (including iSGLT2) in real-life settings in patients hospitalized for decompensated heart failure.

Official Title
-----------------
Optimizing Treatments for Heart Failure During Hospitalization

Conditions
-----------------
Decompensated Heart Failure

Intervention / Treatment
-----------------
* Other: Hospitalized patient for decompensated heart failure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient ≥ 18 years Hospitalized (≥24h) for decompensated heart failure in cardiology. Exclusion Criteria: Patient opposition participation in research and use of data.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Hospitalized patient for decompensated heart failure|Describe the evolution of heart failure medications during hospitalization for decompensated heart failure.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prescription score | Prescription score, ranging from 0 to 10, each type of heart failure treatment (IEC/ARA2, Sacubitril, betablockers, SGLT2i, MRA) being evaluated on a scale of 2. | During hospitalisation for decompensated heart failure (up to 10 days) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum concentration of creatinine | Creatinine measured at admission and discharge | During hospitalisation for decompensated heart failure (up to10 days) | 
| serum concentration of potassium | Potassium measured at admission and discharge | During hospitalisation for decompensated heart failure (up to 10 days) | 
| Concentration of hemoglobin | hemoglobin measured at admission and discharge | During hospitalisation for decompensated heart failure (up to 10 days) | 
| All cause Death |  | 6 months | 
| Rate of hospitalization for heart failure |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Decompensated heart failure
Coenzyme Q10 and Dentoalveolar Cyst

Study Overview
=================
Brief Summary
-----------------
10 patients in each group will undergo cyst removal under local anesthesia. After cyst removal, the cystic cavity will be filled with placebo gel in the control group or coenzyme gel in the coenzyme group. Bone density and volume will be assessed by cone beam CT immediately postoperative and 6months later for all patients

Official Title
-----------------
The Effect of Coenzyme Q10 on Bone Regeneration in Jaw Defect After Cyst Enculation: A Randomized Controlled Clinical Trial

Conditions
-----------------
Cyst, Jaw

Intervention / Treatment
-----------------
* Drug: Coenzyme Q10
* Drug: control group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with critical-size jaw cysts Medically stable No cystic lesion recurrence Exclusion Criteria: Cystic lesion recurrence Medical problem

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: coenzyme group<br> | Drug: Coenzyme Q10<br>* cystic jaw defect filled with coenzyme Q10 gel<br>|
| Placebo Comparator: control group<br> | Drug: control group<br>* cystic jaw defect filled with placebo gel<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bone density | measure the bone density of new bone in the cystic cavity at 6 months by cone beam CT | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bone volume | measure the bone volume in the defect by cone beam CT at 6 months | 6months |
Evaluation of Some Inflammatory Markers in Autism Spectrum Disorders

Study Overview
=================
Brief Summary
-----------------
Evaluate some Inflammatory markers [IL-6, IL-8, TNF_alpha] in children with autism spectrum disorder

Detailed Description
-----------------
several studies have suggested a correlation between ASD and abnormal immune activation (9) For instance, there is a high incidence of autistic subjects in families with other autoimmune disorders such as celiac disease and rheumatoid arthritis, suggesting a potential role for immune dysfunction in the pathophysiology of ASD High levels of IL-6 in the brain could determine alterations of synapse formation, dendritic spine development, and neuronal circuit balance [13], while in plasma they have been associated with increased stereotypical behaviors and with regressive forms of ASD

Official Title
-----------------
Evaluation of Some Inflammatory Markers in Autism Spectrum Disorders

Conditions
-----------------
Autism Spectrum Disorder

Intervention / Treatment
-----------------
* Other: inflammatory marker in autism spectrum disorder


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 50 patients aged 3_18 years, equally sex distributed, who visit pediatric neurology outpatients clinic with autistic disorder at assiut university hospital will enrolled in this study and 50 controls . (According to DSM IV and ADT-R) Exclusion Criteria: : Asperger syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), chronic seizures and recent infection and patients with congenital anomalies

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| children with autism spectrum disorder<br>: 50 patients aged 3_18 years, equally sex distributed, who visit pediatric neurology outpatients clinic with autistic disorder at assiut university hospital will enrolled in this study and 50 controls . (According to DSM IV and ADT-R) | Other: inflammatory marker in autism spectrum disorder<br>* Evaluate some Inflammatory markers [IL-6, IL-8, TNF_alpha] in children with autism spectrum disorder<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| inflammatory marker in autism | Evaluate some Inflammatory markers [IL-6, IL-8, TNF_alpha] in children with autism spectrum disorder | baseline |
Human Phenotype Project Study Protocol

Study Overview
=================
Brief Summary
-----------------
This is a prospective study aimed at recruiting 30,000 individuals, aged 40-70 years old, and following them longitudinally for 25 years with repeated measurements. The basic follow-up frame will include a visit to the Clinical Test Center (CTC) every two years and a phone interview every other year (on uneven years). Sample collection and biobanking will be performed every two years and online questionnaires will be filled out on an annual basis. The primary goals are to study the variation observed across different individuals in disease susceptibility, clinical phenotypes, and therapeutic responses. The study aims at studying the complex interplay and relative contribution of different omics, physiological characteristics and lifestyle on disease pathogenesis and progression and to evaluate how these effects are mediated.

Official Title
-----------------
Longitudinal Collection of Observational Clinical and Lifestyle Data

Conditions
-----------------
Adult Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 18+, males and females. Exclusion Criteria: Pregnancy. Mentally disabled or in general legally non-competent. Prisoner or soldier. Soldiers: mandatory service only Active cancer Fertility Treatments (current) Hepatitis ( B, C), chronic or acute HIV Liver cirrhosis Dialysis Unstable medical conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adult disease | Development of medical conditions based on participant's self-reporting coded to ICD11. | 25 years |
Hand Function Impairment in Systemic Sclerosis: Outcomes, Mechanisms and Experience (HANDSOME)

Study Overview
=================
Brief Summary
-----------------
Almost 90% of systemic sclerosis (SSc) patients experience hand function limitation, which leads to impaired daily functioning and work participation. An important cause of impaired hand function are contractures of the hand, which are reported in up to a half of patients. With this longitudinal cohort study in patients with SSc and VEDOSS (very early diagnosis of systemic sclerosis) the investigators aim to gain more insight into processes involved in hand function impairment.

Official Title
-----------------
Hand Function Impairment in Systemic Sclerosis: Outcomes, Mechanisms and Experience (HANDSOME) Study

Conditions
-----------------
Systemic Sclerosis

Intervention / Treatment
-----------------
* Diagnostic Test: Imaging, blood samples, fuctional tests and physical examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Exclusion Criteria: Patients with diabetic cheiroarthropathy and Dupuytren's disease, based on expert opinion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| VEDOSS<br>defined as RP, presence of SSc specific autoantibodies (ACA, ATA, ARA), puffy fingers and abnormal nailfold capillaroscopy (giant capillaries or capillary loss with or without haemorrhages), but not fulfilling the EULAR-ACR 2013 classification criteria for SSc | Diagnostic Test: Imaging, blood samples, fuctional tests and physical examination<br>* Imaging, blood samples, fuctional tests and physical examination<br>|
| SSc with disease duration of < 4 years without hand contractures<br> | Diagnostic Test: Imaging, blood samples, fuctional tests and physical examination<br>* Imaging, blood samples, fuctional tests and physical examination<br>|
| SSc with hand contractures<br> | Diagnostic Test: Imaging, blood samples, fuctional tests and physical examination<br>* Imaging, blood samples, fuctional tests and physical examination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of risk factors for hand function impairment in systemic sclerosis (SSc) patients with early disease, very early disease and established hand impairment (contractures) at 2 years follow-up |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify underlying mechanisms |  | 2 years | 
| - Validation of the Dutch PASTUL questionnaire |  | 2 years |
Sacral Neuromodulation in Neurogenic Patients

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to evaluate efficacy and safety of sacral neuromodulation in neurogenic patients compared to non-neurogenic (idiopathic) patients. [. The main question[s] it aims to answer are: determine efficacy and safety of the therapy in neurogenic patients. compare outcomes of the therapy to idiopathic patients. If there is a comparison group: Researchers will compare the outcomes of the therapy between the neurogenic and non-neurogenic subset of patients.

Official Title
-----------------
Efficacy and Safety of Sacral Neuromodulation With InterStim II in Neurogenic Bladder and/or Bowel Patients

Conditions
-----------------
Neurogenic Bladder, Neurogenic Bowel, Urge Incontinence, Overactive Bladder, Retention, Urinary, Fecal Incontinence

Intervention / Treatment
-----------------
* Device: InterStim II


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent InterStim II advanced evaluation for approved indication Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neurogenic Patients<br>Patients with underlined relevant neurologic condition, with either neurogenic bladder or bowel, after advanced evaluation of InterStim II | Device: InterStim II<br>* Sacral neuromodulation<br>|
| Idiopathic<br>Patients without underlined relevant neurologic condition, after advanced evaluation of InterStim II | Device: InterStim II<br>* Sacral neuromodulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease of at least 50% in number of catheterizations per day |  | 1 year | 
| Decrease of at least 50% in number of fecal incontinence episodes |  | 1 year | 
| Decrease of at least 50% in number of urge urinary incontinence episodes |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of revision surgeries |  | 1 year | 
| number of follow-up visits for programming and/or troubleshooting |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sacral Neuromodulation, Neurogenic Bladder, Neurogenic Bowel
Prognostic Value of Biomarkers in Polyneuropathy.

Study Overview
=================
Brief Summary
-----------------
Biomarkers for prognosis of patients with polyneuropathy.

Detailed Description
-----------------
AIM: To investigate biomarkers' use as a prognostic tool in polyneuropathy patients. STUDY DESIGN: Prospective cohort study of patients with polyneuropathy. METHODS: 200 patients with polyneuropathy will be examined with physical tests, medical examination, questionnaires, and blood biomarkers at baseline and at 1-year follow-up, and 2-year follow-up. ANALYSIS: We will calculate the odds of disease progression after 2 years depending on biomarkers levels at baseline using multiple logistic regression with sex and age adjustment. Diagnostic performance of the physical tests and biomarkers for prediction of disease progression will be assessed by Receiver Operating Characteristic Curve analysis with the area under the curve.

Official Title
-----------------
The Prognostic Value of Blood Biomarkers for Patients With Polyneuropathy.

Conditions
-----------------
Polyneuropathies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Minimum 18 years old. Diagnosed with polyneuropathy, confirmed by nerve conduction study. Can read and understand Danish. Exclusion Criteria: Inability to perform physical tests due to comorbidity not associated to the patient's polyneuropathy. Polyneuropathy due to

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease Severity | Primary outcome is disease severity | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PROM | Secondary outcome is patient reported outcomes. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
polyneuropathy, biomarkers, cohort study